Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 9, Issue 12, pp. 1696-1707
PubMed
Published By
Print ISSN
Online ISSN
History
- Received June 5, 2019
- Revision received August 26, 2019
- Accepted September 26, 2019
- Published first October 1, 2019.
Article Versions
- Previous version (October 1, 2019 - 05:46).
- Previous version (November 15, 2019 - 06:06).
- You are viewing the most recent version of this article.
Copyright & Usage
©2019 American Association for Cancer Research.
Author Information
- Richard D. Kim1,
- Debashis Sarker2,
- Tim Meyer3,
- Thomas Yau4,
- Teresa Macarulla5,
- Joong-Won Park6,
- Su Pin Choo7,
- Antoine Hollebecque8,
- Max W. Sung9,
- Ho-Yeong Lim10,
- Vincenzo Mazzaferro11,
- Joerg Trojan12,
- Andrew X. Zhu13,
- Jung-Hwan Yoon14,
- Sunil Sharma15,
- Zhong-Zhe Lin16,
- Stephen L. Chan17,
- Sandrine Faivre18,
- Lynn G. Feun19,
- Chia-Jui Yen20,
- Jean-Francois Dufour21,
- Daniel H. Palmer22,
- Josep M. Llovet9,23,
- Melissa Manoogian24,
- Meera Tugnait25,
- Nicolas Stransky25,
- Margit Hagel25,
- Nancy E. Kohl25,
- Christoph Lengauer25,
- Cori Ann Sherwin25,
- Oleg Schmidt-Kittler25,
- Klaus P. Hoeflich25,
- Hongliang Shi25,
- Beni B. Wolf25 and
- Yoon-Koo Kang26,*
- 1H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
- 2King's College London, London, United Kingdom.
- 3University College London, London, United Kingdom.
- 4Queen Mary Hospital, Hong Kong, China.
- 5Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain.
- 6National Cancer Center Korea, Goyang, South Korea.
- 7National Cancer Centre Singapore, Singapore.
- 8Institute Gustav Roussy, Villejuif, France.
- 9Mount Sinai Liver Cancer Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
- 10Samsung Medical Center, Sungkyunkwan University, Seoul, Korea.
- 11University of Milan, Department of Oncology and Instituto Nazionale Tumori, IRCCS Foundation, Department of Surgery, HPB Surgery and Liver Transplantation, Milan, Italy.
- 12Universitätsklinikum Frankfurt, Frankfurt, Germany.
- 13Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
- 14Seoul National University Hospital, Seoul, South Korea.
- 15Huntsman Cancer Institute, Salt Lake City, Utah.
- 16National Taiwan University Hospital, Taipei, Taiwan.
- 17State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.
- 18Hôpitaux Universitaires Paris Nord Val de Seine, Paris, France.
- 19University of Miami, Miami, Florida.
- 20National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- 21University Clinic for Visceral Surgery and Medicine, Inselspital Bern, Bern, Switzerland.
- 22Liverpool Experimental Cancer Medicine Centre, Liverpool, United Kingdom.
- 23Translational Research in Hepatic Oncology Group, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain.
- 24Roche Tissue Diagnostics, Tucson, Arizona.
- 25Blueprint Medicines Corporation, Cambridge, Massachusetts.
- 26Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
- ↵*Corresponding Author:
Yoon-Koo Kang, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. Phone: 82-2-3010-3230; Fax: 82-2-3010-8772; E-mail: ykkang{at}amc.seoul.kr
December 2019
Volume 9, Issue 12
Volume 9, Issue 12
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Jump to section
Advertisement